Abstract: This application provides a detection method for electrode plate, a detection apparatus for electrode plate, a stacking system, a detection device, and a computer-readable storage medium, where the electrode plate includes a coated portion and an uncoated portion located on at least one side of the coated portion in a longitudinal direction. The detection method includes: step S1000: obtaining dimensional parameters D1 . . . DN at different detection positions P1 . . . PN of the uncoated portion in a transverse direction perpendicular to the longitudinal direction; and step S2000: comparing the dimensional parameters D1 . . . DN with a dimensional detection standard S to determine whether the uncoated portion is folded, where N is a positive integer, and N is greater than or equal to 2.

Abstract: A monolithic integrated multi-segment cascade optical frequency comb and its chip are disclosed, which belongs to the technical field of sensing detection, quantum information and optical communication technology. The optical frequency comb includes a first semiconductor passive mode-locking laser, a semiconductor optical amplifier, and a second semiconductor passive mode-locking laser sequentially integrated and connected; the first semiconductor passive mode-locking laser includes a first reverse bias absorption area integrated with an optogalvanic distribution grating and a first gain cavity length extender (coupled multi-ring or multi-disk); the second semiconductor passive mode-locking laser includes a second reverse bias absorption area and a second gain cavity length extender (coupled multi-ring or multi-disk); each structure is connected to each other by electrical isolation grooves.

Abstract: A DNA and RNA nucleic acid co-extraction and detection system includes a nucleic acid extraction system, a sealing, transferring and mixing system, a nucleic acid detection system and a control system, wherein the nucleic acid extraction system, the sealing, transferring and mixing system and the nucleic acid detection system are all connected to the control system; the nucleic acid extraction system comprises a carry basket for loading an extraction reagent strip and a sample tube, a consumable-material supply module, a reagent kit loading module, a barcode scanning device for automatically inputting barcode information, a magnetic absorption incubation device, and an automatic sample addition device for transferring a liquid to a reaction chamber of the extraction reagent strip or a PCR tube and sealing the PCR tube; the sealing and transferring system comprises a PCR transferring device for grabbing and driving a PCR tube to move, and a high-speed mixing device.

Abstract: Computing architecture comprises an off-chip memory, an on-chip cache unit, a prefetching unit, a global scheduler, a transmitting unit, a pre-recombination network, a post-recombination network, a main computing array, a write-back cache unit, a data dependence controller and an auxiliary computing array. The architecture reads data tiles into an on-chip cache in a prefetching mode, and performs computing according to the data tiles; in the computing process of the tiles, a tile exchange network is adopted to recombine a data structure, and a data dependence module is arranged to process a data dependence relationship possibly existing between different tiles. According to the computing architecture, the data utilization rate can be increased, the data processing flexibility is improved, and therefore Cache Miss is reduced, and the memory bandwidth pressure is reduced.

Abstract: A method for event-triggered distributed reinforcement learning for unit commitment optimization and dispatch to solve the waste problem of unit resources includes obtaining a unit commitment optimization and dispatch model, constructing a fixed action set under preset constraint conditions, and selecting optimal power of each unit; transforming constraint conditions into projection constraints, and projecting the virtual generation power to a corresponding constraint range, to obtain actual generation power of each unit within the constraint range; calculating corresponding rewards based on cost under actual generation power of each unit without bandwidth constraints, and updating local Q values of each unit in a Q table according to Q-learning algorithms, to obtain an optimal action of each unit without bandwidth constraints; and under the constraint conditions of considering bandwidths, obtaining an optimal solution, meeting limited bandwidth constraint conditions, to the unit commitment optimization and d

Abstract: Computing architecture comprises an off-chip memory, an on-chip cache unit, a prefetching unit, a global scheduler, a transmitting unit, a pre-recombination network, a post-recombination network, a main computing array, a write-back cache unit, a data dependence controller and an auxiliary computing array. The architecture reads data tiles into an on-chip cache in a prefetching mode, and performs computing according to the data tiles; in the computing process of the tiles, a tile exchange network is adopted to recombine a data structure, and a data dependence module is arranged to process a data dependence relationship possibly existing between different tiles. According to the computing architecture, the data utilization rate can be increased, the data processing flexibility is improved, and therefore Cache Miss is reduced, and the memory bandwidth pressure is reduced.

Abstract: Systems and methods for change in language-based textual analysis are disclosed. In one embodiment, in an information processing apparatus comprising at least one computer processor, a method for change in language-based textual analysis may include: (1) retrieving, from a data source, a first document of a first type; (2) retrieving, from the data source, a second document of the first type, the second document being subsequent in time to the first document; (3) identifying changes between the first document and the second document; (4) calculating a change score based on the changes; and (5) providing the change score to a downstream system for projecting a performance of an investment associated with the first document.

Abstract: This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Abstract: This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Abstract: This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Abstract: This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Abstract: The invention encompasses compounds having formula I or II and the compositions and methods using these compounds in the treatment of conditions in which inhibition of PKC and PKD is therapeutically useful.

Abstract: This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Abstract: This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Abstract: The present invention provides 3-hydroxyphenyl-2,4-pyrimidinediamine compounds of formula I, as well as related compositions and methods for treating a variety of autoimmune diseases.

Abstract: This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Abstract: This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Abstract: The present invention provides 3-hydroxyphenyl-2,4-pyrimidinediamine compounds of formula I, as well as related compositions and methods for treating a variety of autoimmune diseases.

Abstract: The invention encompasses compounds having formula I or II and the compositions and methods using these compounds in the treatment of conditions in which inhibition of PKC and PKD is therapeutically useful.

Abstract: The present invention provides 3-hydroxyphenyl-2,4-pyrimidinediamine compounds of formula I, as well as related compositions and methods for treating a variety of autoimmune diseases.